基层医疗机构抑郁识别与治疗的结构化方法:VitalSign6项目
在美国一个大都市区的16家基层诊所开展质量改进项目,对25,000例≥12岁患者用PHQ-2筛查抑郁,17.3%筛查阳性。阳性者中56.1%被临床医生诊断为抑郁障碍;入组≥18周者64.8%启动基于测量的药物治疗。随访≥3次者缓解率达41.7%,但脱访显著影响结局。
要点
- PHQ-2筛查阳性率17.3%,其中56.1%被临床诊断为抑郁障碍。
- 入组≥18周者64.8%启动基于测量的药物治疗,8.9%转诊外部。
- 随访1、2、≥3次者缓解率分别为20.3%、31.6%、41.7%。
核心结论
- 常规筛查和治疗后,随访≥3次者缓解率较高,但脱访是影响结局的重要问题。
研究设计与样本
- 回顾性分析纳入美国大都市区16家基层诊所质量改进项目中首批25,000例≥12岁、接受PHQ-2筛查的患者。
主要发现
- 25,000例中17.3%(4,325/25,000)筛查阳性(PHQ-2>2)。
- 阳性者中56.1%(2,426/4,325)被临床医生诊断为抑郁障碍。
- 入组≥18周者中64.8%启动基于测量的药物治疗,8.9%转诊外部。
- 启动药物治疗的1,400例中,45.5%、30.2%、12.6%、11.6%分别有0、1、2、≥3次随访。
- 随访1、2、≥3次者缓解率分别为20.3%(86/423)、31.6%(56/177)、41.7%(68/163)。
关键数值与推荐
- PHQ-2>2定义为筛查阳性。
- 临床诊断抑郁障碍后入组≥18周者评估治疗启动和随访情况。
- 基于测量的药物治疗启动比例为64.8%,外部转诊比例为8.9%。
临床怎么用
- 在基层诊所可用PHQ-2进行抑郁初筛,阳性者进一步评估并启动结构化治疗。
- 应关注非白人、药物滥用筛查阳性、症状较轻及年轻患者,主动减少脱访。
- 增加随访次数与更高缓解率相关,需建立随访管理机制。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This report describes outcomes of an ongoing quality-improvement project (VitalSign6) in a large US metropolitan area to improve recognition, treatment, and outcomes of depressed patients in 16 primary care clinics (6 charity clinics, 6 federally qualified health care centers, 2 private clinics serving low-income populations, and 2 private clinics serving patients with either Medicare or private insurance). METHODS: Inclusion in this retrospective analysis was restricted to the first 25,000 patients (aged ≥12 years) screened with the 2-item Patient Health Questionnaire (PHQ-2) in the aforementioned quality-improvement project. Further evaluations with self-reports and clinician assessments were recorded for those with positive screen (PHQ-2 >2). Data collected from August 2014 though November 2016 were available at 3 levels: (1) initial PHQ-2 (n = 25,000), (2) positive screen (n = 4,325), and (3) clinician-diagnosed depressive disorder with 18 or more weeks of enrollment (n = 2,160). RESULTS: Overall, 17.3% (4,325/25,000) of patients screened positive for depression. Of positive screens, 56.1% (2,426/4,325) had clinician-diagnosed depressive disorder. Of those enrolled for 18 or more weeks, 64.8% were started on measurement-based pharmacotherapy and 8.9% referred externally. Of the 1,400 patients started on pharmacotherapy, 45.5%, 30.2%, 12.6%, and 11.6% had 0, 1, 2, and 3 or more follow-up visits, respectively. Remission rates were 20.3% (86/423), 31.6% (56/177), and 41.7% (68/163) for those with 1, 2, and 3 or more follow-up visits, respectively. Baseline characteristics associated with higher attrition were: non-white, positive drug-abuse screen, lower depression/anxiety symptom severity, and younger age. CONCLUSION: Although remission rates are high in those with 3 or more follow-up visits after routine screening and treatment of depression, attrition from care is a significant issue adversely affecting outcomes.
引用
- Jha MK, Grannemann BD, Trombello JM, et al. A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. Ann Fam Med. 2019. PMID: 31285210. doi:10.1370/afm.2418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。